Dr Reddy's Laboratories Ltd (ADR) (N:RDY)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| Company Contact | |
| Address: | 8-2-337, Road No.3 Banjara Hills HYDERABAD 500034 |
| Tel: | N/A |
| Website: | https://www.drreddys.com |
| IR: | See website |
| Key People | ||
| Kallam Satish Reddy Chairman of the Board | Phanimitra B. Chief Information Officer | Gunupati Venkateswara Prasad Co-Chairman of the Board, Managing Director |
| Erez Israeli Chief Executive Officer | Parag Agarwal Chief Financial Officer | Patrick Aghanian Chief Executive Officer, European Generics |
| Marc Kikuchi Chief Executive Officer, North America Generics | M. V. Ramana Chief Executive Officer, Branded Markets (India and Emerging Markets) | Deepak Sapra Chief Executive Officer, API and Services | Archana Bhaskar Chief Human Resource Officer |
| Business Overview |
| Dr. Reddy's Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company's segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company's business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). |
| Financial Overview |
| For the six months ended 30 September 2023, Dr Reddy's Laboratories Ltd (ADR) revenues increased 18% to RS136.19B. Net income increased 25% to RS28.83B. Revenues reflect Global Generics segment increase of 21% to RS121.17B, United States segment increase of 38% to RS66.17B, Russia segment increase of 25% to RS11.43B. Net income benefited from Fair value gain on financial instruments increase from RS78M to RS1.53B (income). |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.